Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

With yields between 3.4% and 6.8%, you'll need to think carefully about the highest yields in the Dow before you buy them.

But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

I've identified three stocks in the S&P 500 index that look like variations on that narrative, and they happen to be the ...

Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new ...

The Prudent Speculator is an investment newsletter that has been published monthly since 1977. Buckingham and his team run four value-stock portfolios. The flagship Prudent Speculator Portfolio has ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

S&P 500 heads for weakest November since 2021 as AI fears hit stocks; Albemarle and Eli Lilly surge while Super Micro and ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...

Len Yaffee says Eli Lilly stock will find it hard to push any higher from here. The Kassef Capital's chief executive ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar ...